Kadmon Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KDMN research report →
Price Chart
About the company
Kadmon Holdings operates as a biopharmaceutical firm, focusing on the discovery, development, and commercialization of small molecule compounds and biologics, primarily to address inflammatory and fibrotic disorders. Its leading therapeutic asset is KD025, an orally administered selective inhibitor of rho-associated coiled-coil kinase 2 (ROCK2), which is currently undergoing Phase II clinical evaluation for chronic graft-versus-host disease and various fibrotic conditions. Another key oral ROCK inhibitor, KD045, is also in development for fibrotic diseases.
- CEO
- Harlan Waksal
- IPO
- 2016
- Employees
- 127
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on KDMN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -14.39
- PEG
- 0.82
- P/S
- 0.00
- P/B
- 13.61
- EV/EBITDA
- 0.48
- Div Yield
- 0.00%
- Gross Margin
- 75.86%
- Op Margin
- -1234.09%
- Net Margin
- -1314.10%
- ROE
- -77.31%
- ROIC
- -73.38%
Latest fiscal year · YoY change
- Revenue
- $8.29M+62.7%
- Gross Profit
- $6.29M+65.2%
- Op Income
- $-102,281,000
- Net Income
- $-108,913,000-77.5%
- EPS
- $-0.66-43.5%
- OCF Growth
- -9.3%
- FCF Growth
- -9.2%
- 52W High
- $9.50
- 52W Low
- $3.45
- 50D MA
- $8.66
- 200D MA
- $5.35
- Beta
- 1.12
- RSI (14)
- 73
- Avg Volume
- 10.03M
No earnings-call transcripts are available for KDMN yet.
of shares held by institutions
148 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Omni Partners Us LLC | 5.45M | ▲ 5.45M |
| Knott David M | 989.45K | ▲ 151.26K |
| Marshall Wace North America L.P. | 110.85K | ▲ 110.85K |
| Aperio Group, LLC | 29.25K | ▲ 2.65K |
| Pictet Asset Management Ltd | 14.20K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 21 | Waksal Harlan | sell | 177,945 |
| Nov 9, 21 | Waksal Harlan | sell | 655,000 |
| Nov 9, 21 | Waksal Harlan | sell | 982,500 |
| Nov 9, 21 | Waksal Harlan | sell | 2,000,000 |
| Nov 9, 21 | Waksal Harlan | sell | 750 |
| Nov 9, 21 | Waksal Harlan | sell | 1,350,000 |
| Nov 8, 21 | Flowers Cynthia Louise | other | 20,150 |
| Nov 9, 21 | Flowers Cynthia Louise | sell | 10,850 |
| Nov 9, 21 | Flowers Cynthia Louise | sell | 64,935 |
| Nov 9, 21 | Flowers Cynthia Louise | sell | 100,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KDMN coverage
Recent articles, reports, and earnings notes.
No research on KDMN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KDMN report →Sanofi completes acquisition of Kadmon
globenewswire.com · Nov 9
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
accesswire.com · Nov 4
3 Biotech Stocks That Surged in September
fool.com · Oct 5
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting
accesswire.com · Oct 1
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
zacks.com · Sep 30
KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN
prnewswire.com · Sep 21
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Contact the Firm
prnewswire.com · Sep 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.